Leading Australian medical and science organizations have expressed significant concern regarding proposed changes to the Research and Development Tax Incentive. Industry experts warn that the adjustments could stifle innovation and negatively impact the country's life sciences sector, potentially hindering critical medical research and development projects.
Swiss pharmaceutical giant Novartis has officially opened a new state-of-the-art facility in Ljubljana, Slovenia. The site is dedicated to the sterile filling and packaging of complex biologics and xRNA medicines, marking a significant expansion of the company's manufacturing capabilities in Europe to support the production of innovative therapies.
Swiss pharmaceutical company Roche has announced promising clinical trial results for its investigational drug, divarasib. The study evaluated the efficacy of the treatment in patients with non-small cell lung cancer harboring specific KRAS G12C mutations, marking a potential advancement in targeted therapy options for this patient population.
Swiss pharmaceutical company Roche has announced promising clinical trial data for its investigational drug, divarasib. The study evaluated the efficacy of the KRAS G12C inhibitor in patients with non-small cell lung cancer (NSCLC) who have previously undergone standard treatments, marking a potential advancement in targeted cancer therapies.
The Competition Commission of South Africa has referred Adcock Ingram Critical Care to the Competition Tribunal. The regulator alleges the company engaged in excessive pricing of renal dialysis products, violating the Competition Act. The case now moves to the Tribunal for adjudication.
The United States has launched a formal investigation into Germany's pharmaceutical pricing policies. The probe aims to determine if current German regulations unfairly restrict U.S. commerce and disadvantage American pharmaceutical companies operating within the European market, marking a significant development in transatlantic trade relations.
A long-running investigation into the irregular procurement of medical prostheses in Murcia, Spain, has intensified as the case reaches the Regional Assembly. Lawmakers are debating the implications of alleged corruption on public health management and patient rights, following reports of inflated costs and improper selection processes within the regional health service.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expansion of Keytruda (pembrolizumab). This recommendation, which covers the EU, Iceland, Liechtenstein, and Norway, marks a significant step toward authorizing new therapeutic applications for the immunotherapy drug in these regions.
The All India Organisation of Chemists and Druggists (AIOCD) has organized a 24-hour nationwide strike across India. The protest aims to highlight concerns regarding the rapid expansion of online pharmacies and aggressive corporate discounting practices, which the association argues threaten the livelihoods of thousands of small-scale independent medicine retailers.
Biotech company Alvotech has announced the successful conclusion of a routine surveillance inspection by the U.S. Food and Drug Administration (FDA) at its manufacturing facility in Reykjavik, Iceland. The inspection is part of the regulatory process for the company's biosimilar development and production operations.
Brazil's health regulatory agency, Anvisa, has officially authorized the use of Mounjaro (tirzepatide) for pediatric patients. This decision expands treatment options for adolescents aged 10 and older diagnosed with type 2 diabetes in the country, marking a significant development in pediatric endocrinology care within Brazil.
The U.S. Food and Drug Administration has launched proof-of-concept clinical trials utilizing real-time data reporting. This initiative aims to modernize the drug development process, reduce timelines, and improve the efficiency of bringing new, safe, and effective medical treatments to patients in the United States.
President Donald Trump announced a deal with pharmaceutical company Regeneron to reduce the costs of its drug treatments for Medicaid and other federal programs. The agreement is part of broader efforts by the administration to address rising prescription drug prices in the United States and expand access to affordable healthcare options for patients.
Hungarian opposition leader Péter Magyar has announced plans to reclaim state-held shares in major corporations, including Mol Nyrt. and Gedeon Richter Nyrt., currently managed by academic foundations. The proposal aims to return these assets to state control, sparking debate over the governance and management of these significant national economic interests.
Pharmaceutical giants AbbVie and Genentech have joined the White House's TrumpRx initiative, a platform designed to provide Americans with access to discounted prescription medications. This expansion marks a significant development in the administration's efforts to address drug pricing through the digital portal.
Austria has aligned with four other European Union member states to advocate for a bloc-wide windfall tax on energy companies. The proposal aims to mitigate the impact of surging fuel and electricity prices on consumers and businesses by capturing excess profits generated by energy firms during the current market volatility.
The Australian government is assessing the potential impact of new US trade policies, which include a 100 percent tariff on specific pharmaceutical imports. Officials are working to ensure the stability of the Pharmaceutical Benefits Scheme (PBS) and maintain affordable access to essential medicines for all Australians amid shifting international trade dynamics.
The U.S. Food and Drug Administration has granted approval to Eli Lilly for Foundayo, a new once-daily oral GLP-1 receptor agonist designed for chronic weight management. This approval marks a significant expansion in the treatment options available for adults struggling with obesity or overweight conditions, offering an alternative to existing injectable therapies.
The U.S. Food and Drug Administration has granted approval for Foundayo, a new once-daily oral GLP-1 receptor agonist developed by Eli Lilly for chronic weight management. This milestone marks a significant expansion in non-injectable treatment options for patients struggling with obesity and weight-related health conditions in the United States.
The National Health Insurance Authority (NHIA) of Nigeria has entered a strategic partnership with Roche to improve access to essential medicines and specialized care. This collaboration aims to reduce out-of-pocket expenses for patients, particularly those requiring treatment for cancer and other chronic conditions, by integrating innovative therapies into the national health insurance framework.
